Literature DB >> 21180556

Portopulmonary hypertension: challenges in diagnosis and management.

Patrick J Troy1, Aaron B Waxman.   

Abstract

Portopulmonary hypertension is defined as the combination of pulmonary arterial hypertension with portal hypertension and presents management complications in patients awaiting liver transplantation. The combination of these vascular disorders has a marked impact on mortality. At present the recommendations for management are limited because of the paucity of definitive clinical trials. We have reviewed the available data on prevalence, diagnosis and treatment. It is clearly time to more formally approach the study of this patient population.

Entities:  

Keywords:  liver disease; portal hypertension; portopulmonary hypertension; pulmonary hypertension; vasodilators

Year:  2009        PMID: 21180556      PMCID: PMC3002535          DOI: 10.1177/1756283X09338431

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  44 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.

Authors:  I Alam; N M Bass; P Bacchetti; L Gee; D C Rockey
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

Review 3.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

Review 4.  Mediators, cytokines, and growth factors in liver-lung interactions.

Authors:  R J Panos; S K Baker
Journal:  Clin Chest Med       Date:  1996-03       Impact factor: 2.878

5.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

Authors:  M J Krowka; R P Frantz; M D McGoon; C Severson; D J Plevak; R H Wiesner
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

6.  Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells.

Authors:  Y Hirata; T Emori; S Eguchi; K Kanno; T Imai; K Ohta; F Marumo
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

Authors:  Michael D McGoon; Adaani E Frost; Ronald J Oudiz; David B Badesch; Nazzareno Galie; Horst Olschewski; Vallerie V McLaughlin; Michael J Gerber; Chris Dufton; Darrin J Despain; Lewis J Rubin
Journal:  Chest       Date:  2008-09-23       Impact factor: 9.410

8.  Portopulmonary hypertension in decompensated cirrhosis with refractory ascites.

Authors:  F S Benjaminov; M Prentice; K W Sniderman; S Siu; P Liu; F Wong
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

9.  Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension.

Authors:  Michael S Gough; R James White
Journal:  Liver Transpl       Date:  2009-01       Impact factor: 5.799

10.  Experience with inhaled iloprost and bosentan in portopulmonary hypertension.

Authors:  M M Hoeper; H J Seyfarth; G Hoeffken; H Wirtz; E Spiekerkoetter; M W Pletz; T Welte; M Halank
Journal:  Eur Respir J       Date:  2007-07-25       Impact factor: 16.671

View more
  1 in total

1.  Pulmonary vascular complications of chronic liver disease: Pathophysiology, imaging, and treatment.

Authors:  Ali Nawaz Khan; Hamdan Al-Jahdali; Khalid Abdullah; Klaus L Irion; Quratulain Sabih; Alaa Gouda
Journal:  Ann Thorac Med       Date:  2011-04       Impact factor: 2.219

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.